The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
April 12th 2024
Patients with radiographic axial spondyloarthritis (ax-SpA) and a high risk of radiographic progression had similar low progression on both secukinumab and an adalimumab biosimilar.
December 31st 2023
The House has passed a bill that would support state efforts to investigate pregnancy-related deaths and research how to prevent future deaths; a column in The New York Times examined 4 specific drug pricing policies and had 3 health policy experts weigh in on what the outcomes of implementing these policies could be; despite the benefits of using biosimilar filgrastim, the United States has lagged behind other countries in adopting the therapy.
Read More
A generic competitor to the EpiPen will not cost any less than the version that is already on the market; a new service from Amazon will use machine learning to pull key information from patient records; a new report from the European Commission has noted that generic and biosimilar products will be key to curbing wasteful spending in healthcare.
Read More
Saving Costs While Maintaining Quality of Care—The Value of Biosimilars in Oncology
November 8th 2018According to a review published in Cancer Management and Research, biosimilar products present a viable cost-saving tool for providers participating in value-based care programs such as the Medicare Shared Savings Program or the Oncology Care Model.
Read More
This Week in Managed Care: October 26, 2018
October 26th 2018This week, the top managed care news included the Trump administration giving governors the power to overhaul section 1332 waivers under the Affordable Care Act (ACA); CMS disclosed a breach in the portal that agents and brokers use to assist consumers signing up for health coverage under the ACA; about one-third of all US healthcare payments in 2017 were tied to alternative payment models.
Watch
5 Things to Know About the FDA's Biosimilar Action Plan
August 10th 2018Since biosimilars gained a US approval pathway as part of the Affordable Care Act, these follow-on drugs have been widely seen as a key way to address the problem of high-cost biologic drugs. However, cost savings have been disappointing as only 12 biosimilar products have been approved to date, and just 4 have become commercially available. That’s a reality that led FDA Commissioner Scott Gottlieb, MD, to call the US market for biosimilars “anemic.”
Read More
What We're Reading: FDA's Biosimilar Plan; Philly Soda Tax Upheld; Health Subsidy Lawsuit Tossed
July 19th 2018FDA Commissioner Scott Gottlieb, MD, announced the release of the agency’s Biosimilar Action Plan; Philadelphia’s tax on soda and other sweetened beverages has been upheld by the Pennsylvania Supreme Court; a federal judge dismissed a lawsuit by 19 states against the Trump administration over the decision to end cost-sharing subsidies under the Affordable Care Act.
Read More
5 Takeaways From the National Comprehensive Cancer Network's 23rd Annual Conference
March 30th 2018The National Comprehensive Cancer Network (NCCN)’s 23rd Annual Conference, held March 22-24 in Orlando, Florida, brought together stakeholders from across the oncology landscape. Here are 5 key takeaways from the meeting.
Read More
Managed Care Cast and Not So Different, the AJMC® Podcast Series, Give Experts a Forum
March 23rd 2018Both Managed Care Cast, from The American Journal of Managed Care®, and Not So Different, the podcast series from The Center for Biosimilars®, offer in-depth discussions of current healthcare issues.
Read More
This Week in Managed Care: March 9, 2018
March 9th 2018This week, the top managed care stories included Cigna's deal to buy Express Scripts; Seema Verma, Alex Azar, and Scott Gottlieb, MD, made the rounds at health conferences; an analysis finds FDA's accelerated approval pathway has been a success with hematology and oncology drugs.
Watch
Drug Pricing Debate: Panel Talks About Transparency, Legislation
March 9th 2018Does meaningful competition currently exist in the pharmaceutical industry and is there enough transparency on price? This was the crux of the discussion at the 2018 National Health Policy Conference of America’s Health Insurance Plans in Washington, DC.
Read More
5 Things to Know About Biosimilars and Inflammatory Bowel Disease
February 23rd 2018Last week, the European Crohn's and Colitis Organisation held its 13th annual congress in Vienna, Austria. At the meeting, researchers presented new data on using biosimilar anti–tumor necrosis factor therapies in treating Crohn disease and ulcerative colitis, 2 manifestations of inflammatory bowel disease. Here are 5 things to know about the research presented.
Read More
This Week in Managed Care: January 12, 2018
January 12th 2018This week, the top managed care stories included CMS unveiling a new voluntary bundled payment model; coverage from the JP Morgan Healthcare Conference, including immunotherapy's impact on HIV treatment and biosimilars; and news that 2 key diabetes devices will be covered by Medicare.
Watch
5 Things From the 36th Annual JP Morgan Healthcare Conference
January 12th 2018This week, the investors and analysts turned their attention to presentations by business leaders at the 36th Annual JP Morgan Healthcare Conference, held in San Francisco, California. Executives from the pharmaceutical and healthcare worlds showcased their products, pipelines, and visions for the future.
Read More
Express Scripts Is Built for the Future of Healthcare, Says CEO Wentworth
January 10th 2018It’s true, pharmacy benefit managers (PBMs) are complicated, admitted Tim Wentworth, president and CEO of Express Scripts, during his presentation at the JP Morgan Healthcare Conference in San Francisco, California. However, the company is built to succeed in the future of healthcare, he said.
Read More